

Global Markets for Bioengineered Protein Drugs

<https://marketpublishers.com/r/G6212E989A9EN.html>

Date: March 2023

Pages: 185

Price: US\$ 5,500.00 (Single User License)

ID: G6212E989A9EN

Abstracts

Report Scope:

This report aims to provide a comprehensive study of the global market for bioengineered protein drugs, both in terms of quantitative and qualitative data, to help readers develop business/growth strategies, assess the market landscape, analyze their position in the current marketplace and make informed business decisions regarding bioengineered protein drugs. Segmentation is based on the drug type, disease type, and region.

Industry growth drivers, restraints, trends, and opportunities in bioengineered protein drugs are also discussed in detail. The report also provides information on the bioengineered protein drug market competitive landscape, features detailed company profiles, and discusses the impact of COVID-19 on the market.

Report Includes:

28 data tables and 23 additional tables

An up-to-date overview and analysis of the global markets for bioengineered protein drugs

Analyses of the global market trends, with historic market revenue data (sales figures) from 2019-2021, estimates for 2022, forecasts for 2023, and projections of compound annual growth rates (CAGRs) through 2027

Highlights of the emerging technology trends, opportunities and gaps estimating current and future demand for bioengineered protein drugs market, and major regions and countries involved in market developments

Estimation of the actual market size and revenue forecast for global bioengineered protein drugs market in USD million terms, and corresponding market share analysis by drug type, disease type, and region

In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall biopharmaceutical industry

Discussion of the regulatory aspects and standards for bioengineered protein therapeutics, newly approved products, underlying clinical trials for all phases and list of vaccines, and the COVID-19 impact on the progress of this market

Insight into the recent industry structure, competitive aspects of each product segment, increasing investment on R&D activities to develop new and improved therapies, market development strategies, and company value share analysis

Identification of the major companies involved in the production and modification of protein drugs, and analysis of the company competitive landscape based on their recent developments, financial performance, and segmental revenues

Descriptive company profiles of the leading global players, including AbbVie Inc., AstraZeneca plc, GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS) Co., Pfizer Inc., Merck and Co., and Sanofi S.A.

Contents

CHAPTER 1 INTRODUCTION

- 1.1 Study Goals and Objectives
- 1.2 Scope of This Report
- 1.3 Methodology and Information Sources
- 1.4 What's New in This Update?
- 1.5 Geographic Breakdown
- 1.6 Analyst's Credentials
- 1.7 BCC Custom Research
- 1.8 Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

- 3.1 Protein Drugs Overview
- 3.2 Bioengineered Protein Drugs
- 3.3 Manufacturing Technologies
 - 3.3.1 Fractionation/Extraction from Natural Sources (Human/Animal)
 - 3.3.2 Microbial Fermentation and Bioreactors
 - 3.3.3 Transgenics
 - 3.3.4 Mammalian Cell Culture

CHAPTER 4 MARKET DYNAMICS

- 4.1 Market Drivers
 - 4.1.1 Growing and Aging Population
 - 4.1.2 Increasing Prevalence of Chronic Diseases
 - 4.1.3 Advancements in Manufacturing Technologies
 - 4.1.4 New Product Launches and Label Expansions
 - 4.1.5 Premium Pricing
 - 4.1.6 Collaborations and Licensing Agreements
- 4.2 Market Challenges
 - 4.2.1 Evolving Regulatory Scenario
 - 4.2.2 Accelerating Biosimilars Market

CHAPTER 5 MARKET BREAKDOWN BY DRUG TYPE

- 5.1 Overview
- 5.2 Monoclonal Antibodies (mAbs)
 - 5.2.1 Types of mAbs
- 5.3 Peptide Hormones
 - 5.3.1 Types of Peptide Hormones
- 5.4 Vaccines
 - 5.4.1 Types of Vaccines
- 5.5 Fusion Proteins
 - 5.5.1 Types of Fusion Proteins
- 5.6 Blood Factors
 - 5.6.1 Types of Blood Factors
- 5.7 Peptide Antibiotics
 - 5.7.1 Types of Peptide Antibiotics
- 5.8 Cytokines
 - 5.8.1 Types of Cytokines
- 5.9 Therapeutic Enzymes
 - 5.9.1 Types of Therapeutic Enzymes
- 5.10 Global Market for Bioengineered Protein Drugs, by Type
 - 5.10.1 Monoclonal Antibodies (mAbs)
 - 5.10.2 Peptide Hormones
 - 5.10.3 Vaccines
 - 5.10.4 Blood Factors and Peptide Antibiotics
 - 5.10.5 Fusion Proteins
 - 5.10.6 Cytokines
 - 5.10.7 Therapeutic Enzymes

CHAPTER 6 MARKET BREAKDOWN BY DISEASE

- 6.1 Overview
- 6.2 Autoimmune Diseases and Other Immunodeficiency Disorders
- 6.3 Solid Tumors
- 6.4 Diabetes
 - 6.4.1 Type 1 Diabetes
 - 6.4.2 Type 2 Diabetes
 - 6.4.3 Gestational Diabetes
- 6.5 Infectious Diseases
 - 6.5.1 Pneumococcal
 - 6.5.2 Diphtheria, Tetanus

- 6.5.3 Human Papillomavirus (HPV)
- 6.5.4 MMR
- 6.5.5 Influenza
- 6.5.6 Hepatitis A
- 6.5.7 Others
- 6.6 Blood Disorders
 - 6.6.1 Bleeding Disorders
 - 6.6.2 Anemia
 - 6.6.3 Blood Cancer
 - 6.6.4 Paroxysmal Nocturnal Hemoglobinuria
- 6.7 Growth Hormone Disorders, Enzyme Deficiency Disorders, and Infertility
- 6.8 Others
 - 6.8.1 Osteoporosis
 - 6.8.2 Asthma
 - 6.8.3 Eye Disorders and Diseases
 - 6.8.4 Transplants
 - 6.8.5 Cardiovascular Diseases
 - 6.8.6 Respiratory Syncytial Virus Infection
 - 6.8.7 Skin Diseases
- 6.9 Global Market for Bioengineered Protein Drugs, by Disease
 - 6.9.1 Autoimmune Diseases and Other Immunodeficiency Disorders
 - 6.9.2 Solid Tumors
 - 6.9.3 Diabetes
 - 6.9.4 Infectious Diseases
 - 6.9.5 Blood Disorders
 - 6.9.6 Growth Hormone Disorders, Enzyme Disorders, and Infertility
 - 6.9.7 Others

CHAPTER 7 MARKET BREAKDOWN BY REGION

- 7.1 Global Markets for Bioengineered Protein Drugs, by Region
 - 7.1.1 North America Market Revenue, by Drug Type
 - 7.1.2 Europe Market Revenue, by Drug Type
 - 7.1.3 Emerging Markets Revenue, by Drug Type

CHAPTER 8 REGULATORY ASPECTS AND NEW APPROVALS

- 8.1 New Approvals
 - 8.1.1 Monoclonal Antibodies (mAbs)

- 8.1.2 Peptide Hormones
- 8.1.3 Vaccines
- 8.1.4 Blood factors
- 8.1.5 Peptide Antibiotics
- 8.1.6 Therapeutic Enzymes
- 8.1.7 Cytokines
- 8.1.8 Fusion Protein

CHAPTER 9 COMPETITIVE LANDSCAPE

- 9.1 Overview
- 9.2 Blockbuster Bioengineered Protein Pharmaceutical Brands
- 9.3 Monoclonal Antibodies
 - 9.3.1 Market Share
 - 9.3.2 Ten Top-Selling Monoclonal Antibodies
- 9.4 Peptide Hormones
 - 9.4.1 Market Share
- 9.5 Vaccines (Excluding COVID-19)
 - 9.5.1 Market Share
- 9.6 Blood Factors and Peptide Antibiotics
 - 9.6.1 Key Players in Recombinant Blood Factors Market
 - 9.6.2 Key players in Peptide Antibiotics Market
- 9.7 Fusion Proteins
 - 9.7.1 Market Share
- 9.8 Cytokines
 - 9.8.1 Market Share
- 9.9 Therapeutic Enzymes
 - 9.9.1 Market Share

CHAPTER 10 EMERGING TRENDS/UPCOMING TECHNOLOGIES IN THE MARKET

- 10.1 Bi- and Multi-Specific Antibodies
 - 10.1.1 Oral GLP-1 Therapy
 - 10.1.2 Accelerating Rare Disease Research Worldwide
- 10.2 Key Trends in Biopharmaceutical Industry

CHAPTER 11 IMPACT OF COVID-19 PANDEMIC

- 11.1 Overview

11.2 Impact on Bioengineered Protein Drugs Market

11.2.1 Impact on the mAbs Market

11.2.2 Impact on Peptide Hormone Market

11.2.3 Impact on Vaccines Market

11.2.4 Impact on Blood Factors and Peptide Antibiotics Market

11.2.5 Impact on Fusion Protein Market

11.2.6 Impact on Cytokines Market

11.2.7 Impact on Therapeutic Enzyme Market

CHAPTER 12 COMPANY PROFILES

ABBVIE INC.

ADMA BIOLOGICS INC.

AMGEN INC.

ASTRAZENECA PLC

BAYER PHARMACEUTICALS

BIONTECH SE

BRISTOL-MYERS SQUIBB

CSL LTD.

ELI LILLY AND CO.

F. HOFFMANN-LA ROCHE AG

GLAXOSMITHKLINE PLC

GRIFOLS S.A.

JOHNSON & JOHNSON

MERCK & CO., INC.

NOVARTIS AG

NOVO NORDISK A/S

OCTAPHARMA AG

PFIZER INC.

REGENERON PHARMACEUTICALS INC.

SANOFI

TAKEDA PHARMACEUTICAL CO., LTD.

List Of Tables

LIST OF TABLES

Summary Table: Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027

Table 1: Characteristics of Large Molecule/Protein Drugs

Table 2: Bioengineered Protein Drugs vs. Chemically Synthesized Drugs

Table 3: Selected Protein Drugs Made, by Fractionation

Table 4: Selected Therapeutic Drugs Produced by Microbial Fermentation

Table 5: Selected Protein Drugs Produced, by Transgenic Animals, Plants, and Microorganisms

Table 6: Selected Protein Drugs Made, by Cell Culture

Table 7: Number and Distribution of Persons Aged 60+, by Region, 2019 and 2050

Table 8: Global Pipeline Molecules, by Type, Through 2021

Table 9: Advantages and Disadvantages of mAbs

Table 10: Vaccines by Disease Type

Table 11: Percentage of Major Proteins Present in Different Fractions After Cohn's Fractionation Method

Table 12: Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027

Table 13: Global Market for mAbs, by Region, Through 2027

Table 14: Global Market for Peptide Hormones, by Region, Through 2027

Table 15: Global Market for Vaccines (Excluding COVID-19 Vaccines), by Region, Through 2027

Table 16: Global Market for Blood Factors and Peptide Antibiotics, by Region, Through 2027

Table 17: Global Market for Fusion Proteins, by Region, Through 2027

Table 18: Global Market for Cytokines, by Region, Through 2027

Table 19: Global Market for Therapeutic Enzymes, by Region, Through 2027

Table 20: Types of Autoimmune Diseases

Table 21: Types of Cancer by the Tissue of Origin

Table 22: Estimated Numbers for All Cancers, Excluding Non-melanoma Skin Cancer, 2020

Table 23: Global Diabetes Estimates and Projections, 2019-2045

Table 24: Global Market for Bioengineered Protein Drugs, by Disease, Through 2027

Table 25: Global Market for Bioengineered Protein Drugs for Autoimmune Diseases and Other Immunodeficiency Disorders, by Region, Through 2027

Table 26: Global Market for Bioengineered Protein Drugs for Solid Tumors, by Region, Through 2027

Table 27: Global Market for Bioengineered Protein Drugs for Diabetes, by Region, Through 2027

Table 28: Global Market for Bioengineered Protein Drugs for Infectious Diseases, by Region, Through 2027

Table 29: Global Market for Bioengineered Protein Drugs for Blood Disorders, by Region, Through 2027

Table 30: Global Market Bioengineered Protein Drugs for Growth Hormone Disorders, Enzyme Disorders, and Infertility, by Region, Through 2027

Table 31: Global Market for Bioengineered Protein Drugs for Other Diseases, by Region, Through 2027

Table 32: Global Market for Bioengineered Protein Drugs, by Region, Through 2027

Table 33: North American Market for Bioengineered Protein Drugs, by Drug Type, Through 2027

Table 34: European Market for Bioengineered Protein Drugs, by Drug Type, Through 2027

Table 35: Emerging Markets for Bioengineered Protein Drugs, by Drug Type, Through 2027

Table 36: Newly Approved Monoclonal Antibodies (mAbs), January 2021–December 2022

Table 37: Newly Approved Peptide Hormones and Drugs, January 2021–December 2022

Table 38: Newly Approved Vaccines, January 2021–December 2022

Table 39: Vaccine Candidates in Clinical Phase, January 2021–December 2022

Table 40: Newly Approved Blood Factors, January 2021–December 2022

Table 41: Newly Approved Peptide Antibiotics, January 2021–December 2022

Table 42: Newly Approved Therapeutic Enzymes, January 2021–December 2022

Table 43: Newly Approved Cytokines, January 2021–December 2022

Table 44: Newly Approved Fusion Protein, January 2021–December 2022

Table 45: The 30 Top-Selling Bioengineered Protein Drugs, 2021

Table 46: Selected Bi-Specific Antibodies in Phase 3 Clinical Trials, 2023

Table 47: WHO-Approved COVID-19 Vaccine Companies, Technology Adopted

Table 48: Global Market Shares of Leading Vaccine Manufacturers, Including COVID-19 and Excluding COVID-19 Vaccines, 2021

Table 49: Eli Lilly and Co.: Business Segments

Table 50: Pfizer: Biopharma Business Segment

List Of Figures

LIST OF FIGURES

Summary Figure: Global Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027

Figure 1: Approved Antibody Therapeutics in the U.S. and EU, 2010-2021

Figure 2: Global Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027

Figure 3: Global Market Shares of Bioengineered Protein Drugs, by Drug Type, 2021

Figure 4: Global Market for mAbs, by Region, 2019-2027

Figure 5: Global Market for Peptide Hormones, by Region, 2019-2027

Figure 6: Global Market for Vaccines (Excluding COVID-19 Vaccines), by Region, 2019-2027

Figure 7: Global Market for Blood Factors and Peptide Antibiotics, by Region, 2019-2027

Figure 8: Global Market for Fusion Proteins, by Region, 2019-2027

Figure 9: Global Market for Cytokines, by Region, 2019-2027

Figure 10: Global Market for Therapeutic Enzymes, by Region, 2019-2027

Figure 11: Estimated Global Incidence of Blood Cancer, by Type, 2020

Figure 12: Global Market for Bioengineered Protein Drugs, by Disease, 2019-2027

Figure 13: Global Market Shares of Bioengineered Protein Drugs, by Disease, 2021

Figure 14: Global Market for Bioengineered Protein Drugs for Autoimmune Diseases and Other Immunodeficiency Disorders, by Region, 2019-2027

Figure 15: Global Market for Bioengineered Protein Drugs for Solid Tumors, by Region, 2019-2027

Figure 16: Global Market for Bioengineered Protein Drugs for Diabetes, by Region, 2019-2027

Figure 17: Global Market for Bioengineered Protein Drugs for Infectious Diseases, by Region, 2019-2027

Figure 18: Global Market for Bioengineered Protein Drugs for Blood Disorders, by Region, 2019-2027

Figure 19: Global Market for Bioengineered Protein Drugs for Growth Hormone Disorders, Enzyme Disorders, and Infertility, by Region, 2019-2027

Figure 20: Global Market for Bioengineered Protein Drugs for Other Diseases, by Region, 2019-2027

Figure 21: Snapshot of Global Market for Bioengineered Protein Drugs, by Region

Figure 22: Global Market Shares of Bioengineered Protein Drugs, by Region, 2021

Figure 23: North American Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027

Figure 24: North American Market Shares of Bioengineered Protein Drugs, by Drug Type, 2021

Figure 25: European Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027

Figure 26: European Market Shares of Bioengineered Protein Drugs, by Drug Type, 2021

Figure 27: Emerging Markets for Bioengineered Protein Drugs, by Drug Type, 2019-2027

Figure 28: Emerging Markets Shares of Bioengineered Protein Drugs, by Drug Type, 2021

Figure 29: NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022

Figure 30: Share of NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022

Figure 31: Bioengineered Protein Drug Approvals, by Drug Type, 2021 and 2022

Figure 32: Distribution Share of Top 50 Best-Selling Drug Brands, by Drug Type, 2021

Figure 33: Top 50 Best-Selling Drug Brand Revenue Share, by Drug Type, 2021

Figure 34: Top 50 Best-Selling Drugs Brands, by Drug Type, 2021

Figure 35: Global Market Shares of Monoclonal Antibodies, by Company, 2021

Figure 36: Ten Top-Selling Monoclonal Antibodies, 2021

Figure 37: Global Market Shares of Peptide Hormones, by Company, 2021

Figure 38: Global Market Shares of Vaccines (Excluding COVID-19), by Company, 2021

Figure 39: Global Market Shares of Peptide Antibiotics, by Company, 2021

Figure 40: Global Market Shares of Fusion Proteins, by Company, 2021

Figure 41: Global Market Shares of Cytokines, by Company, 2021

Figure 42: Global Market Shares of Therapeutic Enzymes, by Company, 2021

Figure 43: AbbVie Inc.: Annual Revenue, 2019-2021

Figure 44: AbbVie Inc.: Revenue Share, by Business Segment, 2021

Figure 45: AbbVie Inc.: Revenue Share, by Region, 2021

Figure 46: ADMA Biologics Inc.: Annual Revenue, 2019-2021

Figure 47: ADMA Biologics Inc.: Revenue Share, by Business Segment, 2021

Figure 48: ADMA Biologics Inc.: Market Shares, by Region, 2021

Figure 49: Amgen Inc.: Annual Revenue, 2019-2021

Figure 50: Amgen Inc.: Revenue Share, by Product, 2021

Figure 51: Amgen Inc.: Revenue Share, by Region, 2021

Figure 52: AstraZeneca: Annual Revenue, 2019-2021

Figure 53: AstraZeneca: Revenue Share, by Segment, 2021

Figure 54: AstraZeneca: Revenue Share, by Region, 2021

Figure 55: Bayer Pharmaceuticals: Annual Revenue, 2019-2021

- Figure 56: Bayer AG: Revenue Share, by Region, 2021
- Figure 57: BioNTech: Annual Revenue, 2020-2021
- Figure 58: Bristol-Myers Squibb Co.: Annual Revenue, 2019-2021
- Figure 59: Bristol-Myers Squibb Co.: Revenue Share, by Product, 2021
- Figure 60: Bristol-Myers Squibb Co.: Revenue Share, by Region, 2021
- Figure 61: CSL Ltd.: Annual Revenue, 2019-2021
- Figure 62: CSL Ltd.: Revenue Share, by Country, 2021
- Figure 63: CSL Ltd.: Revenue Share, by Business Segment, 2021
- Figure 64: Eli Lilly and Co.: Annual Revenue, 2019-2021
- Figure 65: Eli Lilly and Co.: Revenue Share, by Segment, 2021
- Figure 66: Eli Lilly and Co.: Revenue Share, by Region, 2021
- Figure 67: Roche: Pharmaceutical Division Annual Revenue, 2019-2021
- Figure 68: Roche: Pharmaceuticals Division Revenue Share, by Therapeutic Area, 2021
- Figure 69: Roche: Pharmaceuticals Division Revenue Share, by Region, 2021
- Figure 70: GlaxoSmithKline plc: Pharmaceuticals and Vaccine Segment Annual Revenue, 2019-2021
- Figure 71: GlaxoSmithKline plc: Pharmaceutical Segment Revenue Share, by Therapeutic Area, 2021
- Figure 72: GlaxoSmithKline plc: Vaccine Segment Revenue Share, by Category, 2021
- Figure 73: GlaxoSmithKline plc: Revenue Share, by Region, 2021
- Figure 74: Grifols S.A.: Annual Revenue, 2019-2021
- Figure 75: Grifols S.A.: Revenue Share, by Segment, 2021
- Figure 76: Grifols S.A.: Revenue Share, by Region, 2021
- Figure 77: Johnson & Johnson: Pharmaceutical Division Annual Revenue, 2019-2021
- Figure 78: Johnson & Johnson: Pharmaceutical Division Revenue Share, by Therapeutic Area, 2021
- Figure 79: Johnson & Johnson: Pharmaceuticals Division Revenue Share, by Region, 2021
- Figure 80: Merck & Co., Inc.: Pharmaceutical Segment Annual Revenue, 2019-2021
- Figure 81: Merck & Co., Inc.: Pharmaceutical Segment Revenue Share, by Product, 2021
- Figure 82: Merck & Co., Inc.: Pharmaceutical Segment Revenue Share, by Region, 2021
- Figure 83: Novartis: Annual Revenue, 2019-2021
- Figure 84: Novartis: Revenue Share, by Business Segment, 2021
- Figure 85: Novartis: Revenue Share, by Region, 2021
- Figure 86: Novo Nordisk: Annual Revenue, 2019-2021
- Figure 87: Novo Nordisk: Revenue Share, by Business Segment, 2021
- Figure 88: Novo Nordisk: Revenue Share, by Region, 2021

Figure 89: Octapharma: Annual Revenue, 2019-2021

Figure 90: Pfizer: Annual Revenue, 2019-2021

Figure 91: Pfizer: Biopharma Business Revenue Share, by Segment, 2021

Figure 92: Pfizer: Revenue Share, by Region, 2021

Figure 93: Regeneron Pharmaceuticals Inc.: Annual Revenue, 2019-2021

Figure 94: Regeneron Pharmaceuticals Inc.: Revenue Share, by Product, 2021

Figure 95: Sanofi: Annual Revenue, 2019-2021

Figure 96: Sanofi: Revenue Share, by Business Segment, 2021

Figure 97: Sanofi: Revenue Share, by Region, 2021

Figure 98: Takeda Pharmaceutical: Annual Revenue, 2020-2022

Figure 99: Takeda Pharmaceutical: Revenue Share, by Business Segment, 2022

Figure 100: Takeda Pharmaceutical: Revenue Share, by Region, 2022

I would like to order

Product name: Global Markets for Bioengineered Protein Drugs

Product link: <https://marketpublishers.com/r/G6212E989A9EN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6212E989A9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970